IPSEN, OOO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation)

Completed

Conditions: Post-stroke Arm Spasticity

First Posted Date: 2013-04-25

Last Posted Date: 2020-03-31

Lead Sponsor: Ipsen

Target Recruit Count: 302

Registration Number: NCT01840475

BN83495 Phase I in Post-menopausal Women

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Irosustat (BN83495)

First Posted Date: 2013-04-25

Last Posted Date: 2019-11-22

Lead Sponsor: Ipsen

Target Recruit Count: 50

Registration Number: NCT01840488

Locations: 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷
Institut Georges François Leclerc, Dijon, France
🇫🇷
Centre Eugène Marquis, Rennes, France

and more 2 locations

Somatuline Predictive Factors in Acromegaly and NET

Completed

Conditions: Acromegaly
Neuroendocrine Tumours

Interventions: Drug: Somatuline Autogel® 60, 90 or 120 mg

First Posted Date: 2013-04-25

Last Posted Date: 2019-01-14

Lead Sponsor: Ipsen

Target Recruit Count: 156

Registration Number: NCT01840449

Locations: 🇩🇪
ENDOC, Hamburg, Germany
🇦🇹
University Hospital of Vienna, Vienna, Austria
🇨🇭
University Hospital Basel, Basel, Switzerland

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Phase 1

Completed

Conditions: Metastatic Breast Cancer With Active Brain Metastasis
Solid Tumors
ER/PR Positive Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: Ferumoxytol
Drug: MM-398

First Posted Date: 2013-01-17

Last Posted Date: 2019-11-27

Lead Sponsor: Ipsen

Target Recruit Count: 45

Registration Number: NCT01770353

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
University of Michighan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 4 locations

Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia

Phase 3

Completed

Conditions: Cervical Dystonia

Interventions: Biological: Botulinum toxin type A

First Posted Date: 2012-12-20

Last Posted Date: 2019-08-07

Lead Sponsor: Ipsen

Target Recruit Count: 112

Registration Number: NCT01753336

Locations: 🇺🇸
NeuroTrials Research Inc., Atlanta, Georgia, United States
🇺🇸
Kansas City Bone & Joint Clinic, Kansas City, Kansas, United States
🇺🇸
International Clinical Research Institute, Overland Park, Kansas, United States

and more 38 locations

Phase IV-Cervical Dystonia-INTEREST IN CD2

Completed

Conditions: Cervical Dystonia

Interventions: Biological: Botulinum toxin type A

First Posted Date: 2012-12-20

Last Posted Date: 2020-11-05

Lead Sponsor: Ipsen

Target Recruit Count: 1050

Registration Number: NCT01753349

Locations: 🇮🇱
Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
🇭🇺
Jósa András Oktató Kórház, Nyíregyháza, Hungary
🇵🇹
Centro Hospitalar Lisboa Norte, Lisbon, Portugal

and more 110 locations

Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.

Phase 3

Completed

Conditions: Cervical Dystonia

Interventions: Biological: Botulinum toxin type A
Drug: Placebo

First Posted Date: 2012-12-20

Last Posted Date: 2019-08-07

Lead Sponsor: Ipsen

Target Recruit Count: 134

Registration Number: NCT01753310

Locations: 🇺🇸
Loma Linda University Healthcare, Department of Neurology, Loma Linda, California, United States
🇺🇸
Guilford Neurologic Associates, West Palm Beach, Florida, United States
🇺🇸
NeuroTrials Research Inc., Atlanta, Georgia, United States

and more 39 locations

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin 11.25 mg

First Posted Date: 2012-12-20

Last Posted Date: 2020-12-09

Lead Sponsor: Ipsen

Target Recruit Count: 226

Registration Number: NCT01753297

Locations: 🇨🇳
Chinese PLA General HospitalDepartment of UrologySite #156007, Beijing, China
🇨🇳
West China Hosspital, Sichuan UniversityDepartment of Urology Site #156008, Chengdu, China
🇨🇳
The First Affiliated Hospital of the 3th Military Medical University of PLA (Southwest Hospital) Site # 156010, Chongqing, China

and more 15 locations

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Phase 2

Completed

Conditions: Advanced or Metastatic Hepatocellular Cancer
Advanced or Metastatic Ovarian Cancer
Metastatic Renal Cell Cancer
Advanced or Metastatic Gastric Carcinoma

Interventions: Drug: Tasquinimod

First Posted Date: 2012-12-06

Last Posted Date: 2019-01-08

Lead Sponsor: Ipsen

Target Recruit Count: 201

Registration Number: NCT01743469

Locations: 🇧🇪
Leuven cancer institute (LKI), Herestraat, Leuven, Belgium
🇧🇪
Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
🇨🇦
Juravinski Cancer Centre, 699 Concession St, Hamilton, Ontario, Canada

and more 21 locations

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Phase 2

Terminated

Conditions: Metastatic Castrate Resistant Prostate Cancer

Interventions: Drug: Placebo
Drug: Tasquinimod

First Posted Date: 2012-11-26

Last Posted Date: 2019-11-22

Lead Sponsor: Ipsen

Target Recruit Count: 144

Registration Number: NCT01732549

Locations: 🇫🇷
Centre Leon Berard, Lyon, France
🇭🇺
Bajcsy-Zsilinszky Kórház, Budapest, Hungary
🇭🇺
Országos Onkológia Intézet, Budapest, Hungary

and more 13 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy